6533b7d2fe1ef96bd125ed09

RESEARCH PRODUCT

Metabolomics: An Emerging Approach to Understand Pathogenesis and to Assess Diagnosis and Response to Treatment in Spondyloarthritis

Chiara RizzoFederica CamardaDenise DonzellaLidia La BarberaGiuliana Guggino

subject

psoriatic arthritisQH301-705.5MicrobiotaPsoriatic arthritibiomarkersMetabolomicBiomarkerGeneral MedicineGastrointestinal MicrobiomeAnkylosing spondylitistomatognathic diseasesankylosing spondylitisSpondyloarthritisSpondylarthritisDysbiosisHumansMetabolomicsSpondylitis AnkylosingBiology (General)

description

Spondyloarthritis (SpA) is a group of rheumatic diseases whose pathogenesis relies on a complex interplay between genetic and environmental factors. Over the last several years, the importance of the alteration of the gut microbiota, known as dysbiosis, and the interaction of bacterial products with host immunity have been highlighted as intriguing key players in SpA development. The recent advent of the so called “-omics” sciences, that include metabolomics, opened the way to a new approach to SpA through a deeper characterisation of the pathogenetic mechanisms behind the disease. In addition, metabolomics can reveal potential new biomarkers to diagnose and monitor SpA patients. The aim of this review is to highlight the most recent advances concerning the application of metabolomics to SpA, in particular focusing attention on Ankylosing Spondylitis and Psoriatic Arthritis.

https://doi.org/10.3390/cells11030549